Pancreatic Cancer Research

ResearcherVA Greater Los Angeles Healthcare SystemActive in the last 2 years

James W. Sinnett‐Smith

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0074-7270; OpenAlex author ID A5080480389. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 16

  1. Stress and Obesity Signaling Converge on CREB Phosphorylation to Promote Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-24-0785↗
  2. Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. Co-author DOI 10.1038/s41598-023-43498-9↗
  3. Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy. Co-author DOI 10.1158/1535-7163.mct-21-0964↗
  4. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pa… Co-author DOI 10.1371/journal.pone.0216603↗
  5. Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival. First author DOI 10.1038/s41392-017-0005-2↗
  6. Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model. Co-author DOI 10.1038/s41598-018-24337-8↗
  7. Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice. Co-author DOI 10.1186/s12885-018-4713-y↗
  8. Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism. First author DOI 10.1016/j.surg.2016.12.037↗
  9. Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells. Co-author DOI 10.1158/1541-7786.mcr-17-0023↗
  10. Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. Co-author DOI 10.1371/journal.pone.0184455↗
  11. Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2174/1566524016666151222145551↗
  12. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Ca… First author DOI 10.1371/journal.pone.0114573↗
  13. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Co-author DOI 10.1016/j.bbrc.2012.11.010↗
  14. Metformin inhibits the growth of human pancreatic cancer xenografts. Co-author DOI 10.1097/mpa.0b013e31827aec40↗
  15. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0057289↗
  16. Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells. Co-author DOI 10.1002/jcp.22421↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Enrique Rozengurt · 16 shared papers, 2011–2025 · strength 1.50
  2. Guido Eibl · 11 shared papers, 2013–2025 · strength 1.24
  3. Oscar Joe Hines · 6 shared papers, 2017–2025 · strength 0.73
  4. Yaroslav Teper · 3 shared papers, 2022–2025 · strength 0.63
  5. Xiaoying Sun · 2 shared papers, 2023–2025 · strength 0.45
  6. Hui-Hua Chang · 5 shared papers, 2017–2019 · strength 0.38
  7. Hao Fang · 3 shared papers, 2017–2019 · strength 0.25
  8. Aurelia Lugea Reta · 2 shared papers, 2017–2023 · strength 0.23
  9. Richard T. Waldron · 2 shared papers, 2017–2023 · strength 0.23
  10. Stephen Jacob Pandol · 2 shared papers, 2017–2023 · strength 0.23
  11. David W. Dawson · 3 shared papers, 2017–2018 · strength 0.20
  12. Qinhong Xu · 2 shared papers, 2017–2019 · strength 0.18
  13. Linda Ye · 1 shared paper, 2023 · strength 0.18
  14. Andrea Schmidt · 2 shared papers, 2017–2018 · strength 0.15
  15. Krisztina Kisfalvi · 3 shared papers, 2013 · strength 0.15
  16. Heloisa Prado Soares · 2 shared papers, 2013–2014 · strength 0.09
  17. Mu Xu · 1 shared paper, 2018 · strength 0.08
  18. Jonathan C. King · 1 shared paper, 2018 · strength 0.08
  19. Yinglan Zhao · 1 shared paper, 2017 · strength 0.08
  20. James X. Wu · 1 shared paper, 2016 · strength 0.05
  21. Guisheng Zhou · 1 shared paper, 2016 · strength 0.05
  22. John J. Nemunaitis · 1 shared paper, 2016 · strength 0.05
  23. Francis Charles Brunicardi · 1 shared paper, 2016 · strength 0.05
  24. Gang Li · 1 shared paper, 2017 · strength 0.05
  25. Kazuki Takakura · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.